Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Max Schmauss

Showing results (21-30 of 41) with videos related to

Pageof 5
Sort By:
Pharmacopsychiatry|February 27, 2020
Correction: Comparing Schizophrenia Patients With a Predicted High/Low Risk of Nonresponse Receiving Treatment with Ziprasidone and Haloperidol: A Randomized-Controlled StudyRebecca Schennach, Michael Riedel, Ilja Spellmann, et al.
Current Medical Research and Opinion|July 4, 2012
Flexible dosing with paliperidone ER in the treatment of patients with acutely exacerbated schizophrenia: results from a single-arm, open-label studyMax Schmauss, Vlado Jukić, Alberto Siracusano, et al.
Pharmacopsychiatry|September 21, 2018
Comparing Schizophrenia Patients With a Predicted High/Low Risk of Nonresponse Receiving Treatment with Ziprasidone and Haloperidol: A Randomized-Controlled StudyRebecca Schennach, Michael Riedel, Ilja Spellmann, et al.
International Journal of Psychiatry in Clinical Practice|October 8, 2015
Mobility behaviour and driving status of patients with mental disorders - an exploratory studyAlexander Brunnauer, Verena Buschert, Felix Segmiller, et al.
Psychiatry Research|February 19, 2008
Depression during an acute episode of schizophrenia or schizophreniform disorder and its impact on treatment responseMarkus Jäger, Michael Riedel, Max Schmauss, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|September 14, 2007
Prediction of symptom remission in schizophrenia during inpatient treatmentMarkus Jäger, Michael Riedel, Max Schmauss, et al.
Psychopathology|July 17, 2012
Evaluating depressive symptoms in schizophrenia: a psychometric comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating ScaleRebecca Schennach, Michael Obermeier, Florian Seemüller, et al.
The Psychiatric Quarterly|November 1, 2011
Remission and recovery and their predictors in schizophrenia spectrum disorder: results from a 1-year follow-up naturalistic trialRebecca Schennach, Michael Riedel, Michael Obermeier, et al.
Schizophrenia Research|June 5, 2012
Response trajectories in "real-world" naturalistically treated schizophrenia patientsRebecca Schennach, Sebastian Meyer, Florian Seemüller, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|April 13, 2010
Quality of life and subjective well-being in schizophrenia and schizophrenia spectrum disorders: valid predictors of symptomatic response and remission?Rebecca Schennach-Wolff, Markus Jäger, Michael Obermeier, et al.
Pageof 5

Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
Pharmacopsychiatry|February 27, 2020
Correction: Comparing Schizophrenia Patients With a Predicted High/Low Risk of Nonresponse Receiving Treatment with Ziprasidone and Haloperidol: A Randomized-Controlled StudyRebecca Schennach, Michael Riedel, Ilja Spellmann, et al.
Current Medical Research and Opinion|July 4, 2012
Flexible dosing with paliperidone ER in the treatment of patients with acutely exacerbated schizophrenia: results from a single-arm, open-label studyMax Schmauss, Vlado Jukić, Alberto Siracusano, et al.
Pharmacopsychiatry|September 21, 2018
Comparing Schizophrenia Patients With a Predicted High/Low Risk of Nonresponse Receiving Treatment with Ziprasidone and Haloperidol: A Randomized-Controlled StudyRebecca Schennach, Michael Riedel, Ilja Spellmann, et al.
International Journal of Psychiatry in Clinical Practice|October 8, 2015
Mobility behaviour and driving status of patients with mental disorders - an exploratory studyAlexander Brunnauer, Verena Buschert, Felix Segmiller, et al.
Psychiatry Research|February 19, 2008
Depression during an acute episode of schizophrenia or schizophreniform disorder and its impact on treatment responseMarkus Jäger, Michael Riedel, Max Schmauss, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|September 14, 2007
Prediction of symptom remission in schizophrenia during inpatient treatmentMarkus Jäger, Michael Riedel, Max Schmauss, et al.
Psychopathology|July 17, 2012
Evaluating depressive symptoms in schizophrenia: a psychometric comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating ScaleRebecca Schennach, Michael Obermeier, Florian Seemüller, et al.
The Psychiatric Quarterly|November 1, 2011
Remission and recovery and their predictors in schizophrenia spectrum disorder: results from a 1-year follow-up naturalistic trialRebecca Schennach, Michael Riedel, Michael Obermeier, et al.
Schizophrenia Research|June 5, 2012
Response trajectories in "real-world" naturalistically treated schizophrenia patientsRebecca Schennach, Sebastian Meyer, Florian Seemüller, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|April 13, 2010
Quality of life and subjective well-being in schizophrenia and schizophrenia spectrum disorders: valid predictors of symptomatic response and remission?Rebecca Schennach-Wolff, Markus Jäger, Michael Obermeier, et al.
Pageof 5